$IPSC·8-K

Century Therapeutics, Inc. · Jun 8, 4:10 PM ET

Compare

Century Therapeutics, Inc. 8-K

Research Summary

AI-generated summary

Updated

Century Therapeutics Presents Preclinical iPSC Cell Therapy Data at ADA 2026

What Happened

  • Century Therapeutics, Inc. (IPSC) filed a Current Report on Form 8-K on June 8, 2026 reporting that it presented preclinical data from its iPSC-derived cell therapy platform at the American Diabetes Association (ADA) 2026 Scientific Sessions (June 5–8, 2026) in New Orleans, Louisiana.
  • The company attached a press release (Exhibit 99.1) and the conference presentation slides (Exhibit 99.2) to the filing and noted it has no obligation to update the slides.

Key Details

  • Filing date: June 8, 2026 (Form 8-K, Item 8.01).
  • Event: ADA 2026 Scientific Sessions, held June 5–8, 2026 in New Orleans.
  • Materials filed: Press release (Exhibit 99.1) and presentation slides (Exhibit 99.2).
  • Topic presented: Preclinical data from Century’s iPSC-derived cell therapy platform.

Why It Matters

  • Public presentation and filing make new preclinical data accessible to investors and researchers, providing a clearer view of Century’s pipeline progress in iPSC-derived cell therapy.
  • While this is preclinical (non-clinical) data — not clinical trial results or financial disclosures — it is a non-financial development investors may use to assess R&D momentum and upcoming milestones.

Loading document...